On October 14th, Gansu Yatai Industrial Development (000691.SZ) announced that, based on the principles of complementary advantages and mutually beneficial cooperation, the company has reached a strategic cooperation agreement with the Pingshan Biomedical Research Institute of Southern University of Science and Technology, on the commercialization of the drug green catalysis technology platform intermediate project, signing a comprehensive strategic cooperation agreement in Shenzhen on October 14, 2024. The agreement is valid for 3 years.
The cooperation includes the construction of an active pharmaceutical ingredient intermediate production base; carrying out the design of key chiral intermediate production lines such as efabutamide and tegrelor; Joint development of products for the top 200 global pharmaceutical raw materials, focusing on those with large market sales volume, significant technological improvement space, and high added value.
